Free Trial
NASDAQ:PHVS

Pharvaris (PHVS) Stock Price, News & Analysis

Pharvaris logo
$18.50 +0.52 (+2.89%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$18.14 -0.36 (-1.95%)
As of 07:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pharvaris Stock (NASDAQ:PHVS)

Key Stats

Today's Range
$17.63
$18.50
50-Day Range
$15.46
$18.76
52-Week Range
$11.51
$25.50
Volume
45,346 shs
Average Volume
70,396 shs
Market Capitalization
$967.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.20
Consensus Rating
Buy

Company Overview

Pharvaris Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

PHVS MarketRank™: 

Pharvaris scored higher than 33% of companies evaluated by MarketBeat, and ranked 669th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pharvaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pharvaris has only been the subject of 3 research reports in the past 90 days.

  • Read more about Pharvaris' stock forecast and price target.
  • Earnings Growth

    Earnings for Pharvaris are expected to decrease in the coming year, from ($2.71) to ($3.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pharvaris is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pharvaris is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pharvaris has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Pharvaris' valuation and earnings.
  • Percentage of Shares Shorted

    4.50% of the float of Pharvaris has been sold short.
  • Short Interest Ratio / Days to Cover

    Pharvaris has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pharvaris has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pharvaris does not currently pay a dividend.

  • Dividend Growth

    Pharvaris does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.50% of the float of Pharvaris has been sold short.
  • Short Interest Ratio / Days to Cover

    Pharvaris has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pharvaris has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pharvaris has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Pharvaris this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pharvaris insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Pharvaris' insider trading history.
Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

PHVS Stock News Headlines

Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
See More Headlines

PHVS Stock Analysis - Frequently Asked Questions

Pharvaris' stock was trading at $19.17 at the start of the year. Since then, PHVS shares have decreased by 3.5% and is now trading at $18.50.

Pharvaris N.V. (NASDAQ:PHVS) posted its earnings results on Tuesday, May, 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.09.

Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHVS
CIK
1830487
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$55.00
Low Price Target
$25.00
Potential Upside/Downside
+95.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$145.24 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.54 per share
Price / Book
3.34

Miscellaneous

Free Float
46,099,000
Market Cap
$967.37 million
Optionable
Not Optionable
Beta
-2.82
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PHVS) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners